BANTHINE
LOE ApproachingNDAORALTABLET
Approved
Jul 1951
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BANTHINE is an oral tablet small-molecule drug approved by Takeda in 1951 with an unknown mechanism of action and indication profile. The drug is currently in the late stages of its product lifecycle with loss of exclusivity approaching. Patient population and therapeutic application cannot be determined from available data.
LOE Approaching
As a legacy product approaching loss of exclusivity, BANTHINE brand roles are contracting; teams typically focus on managed decline and generic transition support rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
BANTHINE currently has zero linked job openings, reflecting its late-lifecycle status and minimal active development. Career opportunities on this product are limited to operational support and managed decline activities rather than growth-focused roles.
Brand Manager (managed care)Market Access Specialist
Worked on BANTHINE at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.